Literature DB >> 15930273

Functional analysis of PIK3CA gene mutations in human colorectal cancer.

Tsuneo Ikenoue1, Fumihiko Kanai, Yohko Hikiba, Toshiyuki Obata, Yasuo Tanaka, Jun Imamura, Miki Ohta, Amarsanaa Jazag, Bayasi Guleng, Keisuke Tateishi, Yoshinari Asaoka, Masayuki Matsumura, Takao Kawabe, Masao Omata.   

Abstract

Mutations in the PIK3CA gene, which encodes the p110alpha catalytic subunit of phosphatidylinositol 3-kinase (PI3K), have been reported in human cancers, including colorectal cancer. Most of the mutations cluster at hotspots within the helical and kinase domains. Whereas H1047R, one of the hotspot mutants, is reported to have elevated lipid kinase activity, the functional consequences of other mutations have not been examined. In this study, we examined the effects of colon cancer-associated PIK3CA mutations on the lipid kinase activity in vitro, activation of the downstream targets Akt and p70S6K in vivo and NIH 3T3-transforming ability. Of eight mutations examined, all showed increased lipid kinase activity compared with wild-type p110alpha. All the mutants strongly activated Akt and p70S6K compared with wild-type p110alpha as determined by immunoblotting using phospho-specific antibodies. These mutants also induced morphologic changes, loss of contact inhibition, and anchorage-independent growth of NIH 3T3 cells. The hotspot mutations examined in this study, E542K, E545K, and H1047R, all had high enzymatic and transforming activities. These results show that almost all the colon cancer-associated PIK3CA mutations are functionally active so that they are likely to be involved in carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930273     DOI: 10.1158/0008-5472.CAN-04-4114

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  130 in total

1.  Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.

Authors:  Minghao Sun; Jonathan R Hart; Petra Hillmann; Marco Gymnopoulos; Peter K Vogt
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

Review 2.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 3.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

4.  PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.

Authors:  Arantza Fariña Sarasqueta; Eliane C M Zeestraten; Tom van Wezel; Gesina van Lijnschoten; Ronald van Eijk; Jan Willem T Dekker; Peter J K Kuppen; Ines J Goossens-Beumer; Valery E P P Lemmens; Cornelis J H van de Velde; Harm J T Rutten; Hans Morreau; A J C van den Brule
Journal:  Cell Oncol (Dordr)       Date:  2011-08-10       Impact factor: 6.730

5.  Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.

Authors:  Turgut Dogruluk; Yiu Huen Tsang; Maribel Espitia; Fengju Chen; Tenghui Chen; Zechen Chong; Vivek Appadurai; Armel Dogruluk; Agna Karina Eterovic; Penelope E Bonnen; Chad J Creighton; Ken Chen; Gordon B Mills; Kenneth L Scott
Journal:  Cancer Res       Date:  2015-12-01       Impact factor: 12.701

6.  Markers of resistance to anti-EGFR therapy in colorectal cancer.

Authors:  Walid Shaib; Reena Mahajan; Bassel El-Rayes
Journal:  J Gastrointest Oncol       Date:  2013-09

Review 7.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

Review 8.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

9.  Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.

Authors:  Li Zhao; Peter K Vogt
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

10.  PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.

Authors:  Parminder K Mankoo; Saraswati Sukumar; Rachel Karchin
Journal:  Proteins       Date:  2009-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.